PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma
NK/T-cell Lymphoma
About this trial
This is an interventional other trial for NK/T-cell Lymphoma
Eligibility Criteria
Inclusion Criteria: Pathologically diagnosed NK/T-cell lymphoma based on the WHO classification 2016 Age from 14 to 70 years-old ECOG 0-2 score Patients with a life expectancy of at least 6 months Patient has not been treated before for NK/T cell lymphoma Commit to abide by the research procedures and cooperate with the implementation of the whole process of research Written informed consent Exclusion Criteria: - Subjects who meet any of the following criteria are not eligible for study entry Diagnosed aggressive NK cell leukemia Pregnant or lactating women Liver and kidney insufficiency Other PET/MR contraindications: Those with implanted functional electronic devices such as cardiac pacemakers Carotid aneurysm clipping and other implants are ferromagnetic materials Implanted perfusion devices such as insulin perfusion pumps Those who do not cooperate in examinations such as coma, mental illness, and critically ill patients Those who are claustrophobic Other concurrent and uncontrolled medical conditions that the investigator believes will affect the patient's participation in the study
Sites / Locations
- Ruijin HospitalRecruiting
Arms of the Study
Arm 1
Experimental
PET/MR
This is a prospective, single-arm clinical study. Subjects who meet the inclusion criteria will receive PET/MR examination within 28 days before treatment after signing the informed consent form for pre-treatment evaluation. Stage I/II patients received PET/MR again 21-35 days after 2 and 4 courses of standard treatment for mid-term and final efficacy evaluation. Stage III/IV patients received PET/MR again 21-35 days after 3 and 6 courses of standard treatment for mid-term and final efficacy evaluation. Follow-up assessments are then continued, every 12 weeks for the first year, and every 24 weeks thereafter (clinical symptoms, physical examination, enhanced CT of the cervix, abdomen, and pelvis, and enhanced MR of the nasopharynx) until disease progression (PD), death, withdrawal of informed consent, or study finish. For subjects with suspected PD, histopathological results should be obtained whenever possible to confirm or exclude PD status.